他汀类药物的使用与帕金森病风险
Statin use and the risk of Parkinson disease.
作者信息
Wahner Angelika D, Bronstein Jeff M, Bordelon Yvette M, Ritz Beate
机构信息
Department of Epidemiology, UCLA School of Public Health, 650 Charles E. Young Drive, Los Angeles, CA 90095-1772, USA.
出版信息
Neurology. 2008 Apr 15;70(16 Pt 2):1418-22. doi: 10.1212/01.wnl.0000286942.14552.51. Epub 2008 Jan 9.
OBJECTIVE
To investigate associations between statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).
METHODS
We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.
RESULTS
We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (>or=5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.
CONCLUSION
Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
目的
研究他汀类药物（3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂）的使用与帕金森病（PD）之间的关联。
方法
我们采用基于人群的设计，从加利福尼亚州的三个乡村县招募了312例新发特发性PD病例和342例对照。
结果
我们观察到对照组中他汀类药物的使用频率高于病例组（比值比[OR]为0.45；95%置信区间[CI]为0.29至0.71），且存在强烈的剂量反应关系。在长期（≥5年）使用者中观察到他汀类药物使用与PD之间最强的保护关联（OR为0.37；95%CI为0.18至0.78）。在性别或年龄方面没有差异。除普伐他汀外，我们注意到每种他汀类药物的风险降低了60%至70%。
结论
将这些关联归因于因果关系还为时过早，需要进一步研究来证实他汀类药物在PD中潜在的神经保护作用。
Zotero 插件